CagriSema: two hunger pathways in one injection

The short version

• CagriSema is two medicines in one weekly injection: semaglutide (a GLP-1 medicine, which copies a gut hormone that tells your brain you are full) and cagrilintide (a long-acting copy of amylin, a second fullness hormone).
• People in the main trials lost about 20% of their body weight on average. That is a strong result, though lower than the roughly 25% some had hoped for.
• In a head-to-head trial it did not match tirzepatide (23.0% versus 25.5% weight loss). That trial came after the approval application, so it is not what the FDA is judging.
• It is not approved yet. As of 26 October 2026 it is still under FDA review, with no public decision date. Novo Nordisk expects a decision before the end of 2026.
• Whether it will be approved, and how it will compare in everyday use, is not yet established. Until then it is not available, and there is no legitimate compounded version.

Updated October 2026: status re-checked 26 October 2026. Still under FDA review and not approved; Novo Nordisk's Q4 2026 decision guidance stands (repeated in coverage dated 23 October 2026); no public PDUFA date and no FDA advisory committee announced. Rewrote the summary box in plain English and replaced the supply-focused call to action with a bloodwork-first one.

Updated September 2026 (5): decision watch re-checked 24 September 2026: CagriSema remains under FDA review and unapproved, and there is still no publicly confirmed PDUFA date. That absence is the status worth reporting: company guidance points to a decision by late 2026, but no agency date exists to quote. Dates the REDEFINE 4 readout to February 2026 and states plainly that it did not establish superiority over the comparator.

Updated September 2026 (4): decision watch re-checked 14 September 2026 - CagriSema remains under FDA review, unapproved, with no publicly confirmed PDUFA date. Also reconciles the status date, which appeared as both 4 and 9 September in different parts of this page; all status statements now read 14 September 2026.

Updated September 2026: anchors the expected-decision language to Novo Nordisk's own Form 6-K FY2026, which carries the US CagriSema decision as a stated Q4 2026 regulatory milestone, replacing the looser "late 2026" attribution. Adds a pointer to the filed-approved-available explainer.

Updated September 2026 (2): decision watch re-checked 9 September 2026 - still under review, still unapproved, no PDUFA date published. Aligns the sources block with the Q4 2026 milestone carried in the body, and removes the trial-arm dose figure from the comparator description in line with the no-dosing standard.

Updated September 2026: decision watch re-checked: as of 4 September 2026 CagriSema remains under FDA review and unapproved, with no PDUFA date published. No change to the REDEFINE-4 reading: it missed non-inferiority against tirzepatide.

Updated August 2026: corrects the REDEFINE-4 figures (23.0% vs 25.5% at 84 weeks), states that no PDUFA date has been published and that the circulating "October 2026" date is an unofficial trade estimate, and adds REDEFINE-11 (data expected H1 2027) as the forward watch item.

---

CagriSema is Novo Nordisk's answer to the next generation: rather than a brand-new molecule, it combines two - semaglutide (the active ingredient in Wegovy) plus cagrilintide, a long-acting amylin analog. The logic is that hitting two complementary satiety pathways produces greater and more durable weight loss than GLP-1 alone, with a bonus: an emphasis on preserving lean mass. It finished its pivotal program at around 20% weight loss and its New Drug Application was submitted to the FDA on 18 December 2025. Here's the honest read - including why "about 20%" was both impressive and, against sky-high expectations, a little underwhelming.

Where it stands, as of 26 October 2026. CagriSema (investigational) is not approved. The NDA was submitted on 18 December 2025, based primarily on the efficacy and safety data from REDEFINE 1 and REDEFINE 2, and it remains under FDA review. No PDUFA date has been publicly confirmed by the FDA or by Novo Nordisk - and that absence is the actual status, not a gap in this page. Company guidance points to a US decision by late 2026, carried in Novo's Form 6-K FY2026 as a Q4 2026 regulatory milestone; the "October 2026" date widely repeated in trade coverage is an unofficial estimate, not a published PDUFA date. A stated corporate milestone is a company's expectation, not an agency commitment; treat it accordingly, and treat any specific date you see quoted as unsourced until the FDA or Novo publishes one. Until a decision lands, CagriSema cannot be prescribed, is not available, and has no legitimate compounded version. The decision timeline, and what a PDUFA date actually is, are set out in when will CagriSema be approved?

The head-to-head result - and why it sits outside the filing. In REDEFINE 4, reported in February 2026, CagriSema (investigational) was compared directly with Zepbound (tirzepatide) and reached 23.0% weight loss versus 25.5% at 84 weeks - missing its primary endpoint of non-inferiority on weight loss, and certainly establishing no superiority over the comparator. The timing matters: REDEFINE 4 post-dates the December 2025 filing package, which rests on REDEFINE 1 and REDEFINE 2, so it was not the basis of the submission the FDA is reviewing. That distinction is worth holding onto when reading either optimistic or dismissive coverage. This doesn't make CagriSema a poor option - the amylin pathway is real and tolerability may suit some people - but it does undercut the assumption that a newer combination automatically beats an approved dual agonist. Full context: GLP-1 generations compared.

What it is and how it works

CagriSema is a once-weekly injection (an oral version is also being explored) that pairs:

• Semaglutide - the GLP-1 agonist that suppresses appetite and improves glucose control
• Cagrilintide - an amylin analog that acts on a different satiety pathway, promoting fullness and slowing gastric emptying (see the cagrilintide compound reference)

By targeting two complementary appetite systems, the combination aims to produce greater weight loss than GLP-1 therapy alone - and, importantly, amylin-based approaches are associated with better retention of lean body mass, addressing one of the real weaknesses of rapid weight loss.

The data - and the expectations problem

In its pivotal REDEFINE program, CagriSema (investigational) produced roughly 20% mean weight loss - a strong result that outperforms semaglutide alone and approaches the magnitude once seen mainly with metabolic surgery. The nuance worth being honest about: expectations had been set closer to 25%, so the ~20% readout landed as a disappointment relative to the hype, even though it's an excellent absolute result. It's a useful reminder that pipeline numbers get inflated before the data lands.

REDEFINE 1 and REDEFINE 2 are the two trials underpinning the FDA submission. REDEFINE 4, the tirzepatide comparison described above, came later and is therefore commentary on the drug's competitive position rather than part of the approval package. Its higher CagriSema figure (23.0%) reflects a different trial, a different population and a longer 84-week window than REDEFINE 1's 68 weeks - the two numbers are not directly interchangeable, and only the within-trial comparison against tirzepatide is meaningful.

Side effects and trade-offs

• Gastrointestinal - nausea, vomiting and diarrhea, as with the GLP-1 class, most prominent during dose escalation.
• Two-drug profile - combining mechanisms can mean combined tolerability considerations.
• Class caution - the GLP-1 component carries the thyroid C-cell boxed warning.
• Muscle - better lean-mass retention is a design goal, but muscle protection still matters.

Where it stands

To state it without hedging, in dates:

CagriSema (investigational) is not yet approved - it's under FDA review after the December 2025 filing, making it one of the first next-gen options that could reach patients. Until a decision lands, it isn't available, and there is no legitimate compounded version.

Forward watch item. Beyond the pending US decision, the next substantive readout is REDEFINE 11, an ongoing trial of a higher CagriSema dose with data expected in H1 2027. Whether a higher dose changes the competitive picture is an open question, not a settled one - and nothing about a trial in progress translates into anything a reader should act on.

This is a live decision watch. Regulatory status here can change without notice. Re-check this page within 30 days of the date above.

The bottom line, and where to start

CagriSema combines semaglutide with an amylin medicine to work on two hunger signals at once. It produced around 20% weight loss in its main trials, it did not match tirzepatide head to head, and it is still under FDA review. None of that is a reason to put off a decision about an approved medicine that is available today. The useful next step is the same either way: get a clear picture of your own health first, and talk the options through with your own doctor, who can tell you when CagriSema becomes a real option for you.

Where Vivre Labs fits

Vivre Labs offers semaglutide and tirzepatide, both approved prescription medicines for weight management, and lists cagrilintide with its investigational status stated. We recommend starting with baseline bloodwork, so any choice rests on your own numbers.

Frequently asked questions

What is CagriSema? An investigational once-weekly injection from Novo Nordisk combining semaglutide (a GLP-1 agonist) with cagrilintide (an amylin analog), designed to hit two satiety pathways at once. It's under FDA review, not yet approved.

Is CagriSema approved yet? No. As of 26 October 2026 it remains under FDA review. The NDA was submitted on 18 December 2025. No PDUFA date has been publicly confirmed by the FDA or Novo Nordisk, and that absence is the honest answer to "when" - company guidance points to a decision by late 2026, carried in Novo's own Form 6-K FY2026 as a Q4 2026 regulatory milestone. The "October 2026" date circulating in trade coverage is an unofficial estimate, not a published PDUFA date, and a review can extend. Filed, approved and available are three different things - why a medicine's date is three different dates unpacks the distinction.

How much weight does CagriSema cause you to lose? Around 20% mean body weight in its pivotal program - better than semaglutide alone, though below the ~25% some had anticipated. In the direct comparison against Zepbound (tirzepatide) (REDEFINE 4) it reached 23.0% versus 25.5% at 84 weeks. Figures describe trial populations; they are not a dosing recommendation.

Is CagriSema better than Wegovy? On trial data it produced greater weight loss than semaglutide (Wegovy) alone and may preserve more muscle, by adding the amylin mechanism. It is not yet approved or available.

Did CagriSema beat tirzepatide? No. REDEFINE 4 compared them directly and missed its primary endpoint of non-inferiority on weight loss: 23.0% with CagriSema versus 25.5% with Zepbound (tirzepatide) at 84 weeks. That readout post-dates the FDA filing and was not the basis of the submission - but it is the best available evidence on how the two compare.

Is a higher dose being studied? Yes. REDEFINE 11 is ongoing and is investigating a higher CagriSema dose, with data expected in H1 2027. CagriSema remains investigational, and nothing in an ongoing trial constitutes guidance.

Related reading

• New weight-loss drugs 2026–2027 · Amycretin · Semaglutide · Losing fat, not muscle, on a GLP-1 · Cagrilintide as a bridge or stack, in plain English · Do different mechanisms mean you can combine retatrutide and cagrilintide?
• Part of The Complete Guide to GLP-1s

---

Educational content, not medical advice. CagriSema is investigational and under FDA review; it is not approved. Trial data and regulatory timelines change. Claims for the Malaysian market are subject to MAB requirements. Position stated as of 26 October 2026. Last reviewed: October 2026.

References

• CagriSema (semaglutide + cagrilintide/amylin): Novo Nordisk NDA submitted to FDA 18 December 2025, based primarily on the efficacy and safety data from REDEFINE 1 and REDEFINE 2; ~20% weight loss in the pivotal REDEFINE program; two-satiety-pathway mechanism; lean-mass-retention emphasis. (PharmExec, Novo Nordisk Submits NDA to FDA for CagriSema.)
• REDEFINE 4: head-to-head versus Zepbound (tirzepatide), reported February 2026 - 23.0% vs 25.5% weight loss at 84 weeks; missed the primary endpoint of non-inferiority on weight loss and did not establish superiority over the comparator; readout post-dates the filing package and was not the basis of the submission. (Clinical Trials Arena, Novo Nordisk's CagriSema bested by Lilly's Zepbound in head-to-head trial; Drug Topics; HCPLive.)
• Ad-hoc News, Novo Nordisk's Pipeline Has Three Clocks Ticking, 23 October 2026: company still expects an FDA decision on CagriSema in Q4 2026; CagriSema remains investigational.
• Novo Nordisk, Novo Nordisk files for FDA approval of CagriSema, 18 December 2025: FDA expected to review the application in 2026.
• As of 26 October 2026 CagriSema remains under FDA review and is not approved; no PDUFA date publicly confirmed by the FDA or Novo Nordisk - the absence of a confirmed date is the position of record. Company guidance points to a decision by late 2026; Novo Nordisk carries it as a Q4 2026 regulatory milestone (Form 6-K, FY2026); the frequently cited "October 2026" is an unofficial trade estimate rather than a published PDUFA date.
• REDEFINE 11 ongoing, investigating a higher CagriSema dose; data expected H1 2027.
• GLP-1 class thyroid C-cell boxed warning.

Maintenance note: this article is a live decision watch and is time-sensitive. Re-check within 30 days, and monthly thereafter until the FDA decision lands - specifically for (a) any publicly confirmed PDUFA date, (b) approval, complete response, or extension of the review, (c) any change to Novo Nordisk's expected-decision language, and (d) REDEFINE 11 timing.